Literature DB >> 6356279

Short-term administration of rifampin in the prevention or eradication of infection due to foreign bodies.

K Tshefu, W Zimmerli, F A Waldvogel.   

Abstract

Short-term administration of rifampin was evaluated as a means of preventing or eradicating infection due to foreign bodies. Tissue cages were implanted into guinea pigs and subsequently infected with 10(3) colony-forming units of Staphylococcus aureus Wood 46. Infection developed in all tissue cages. Rifampin was administered thereafter intraperitoneally at a dosage of 7.5 mg/kg every 12 hr for 48 hr, and the tissue-cage fluid was monitored for possible development of infection by quantitative bacteriologic methods for 15 days. In all cases rifampin prevented or eradicated tissue-cage infection if treatment was initiated either 3 hr before or less than or equal to 12 hr after inoculation of microorganisms but was ineffective if initiated greater than 12 hr after inoculation. In cases of failure of treatment, rifampin-resistant variants could be demonstrated. Rifampin seems to prevent or eradicate tissue-cage infection only if given early after bacterial inoculation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6356279     DOI: 10.1093/clinids/5.supplement_3.s474

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  15 in total

1.  Successful single-dose prophylaxis of Staphylococcus aureus foreign body infections in guinea pigs by fleroxacin.

Authors:  N Bouchenaki; P E Vaudaux; E Huggler; F A Waldvogel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

2.  Vancomycin for treatment of infections with methicillin-resistant Staphylococcus aureus: are there alternatives?

Authors:  D Milatovic
Journal:  Eur J Clin Microbiol       Date:  1986-12       Impact factor: 3.267

3.  Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus.

Authors:  J C Lucet; M Herrmann; P Rohner; R Auckenthaler; F A Waldvogel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

4.  Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus.

Authors:  Pierre Vaudaux; Patrice Francois; Carmelo Bisognano; Jacques Schrenzel; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 5.  Role of Rifampin against Staphylococcal Biofilm Infections In Vitro, in Animal Models, and in Orthopedic-Device-Related Infections.

Authors:  Werner Zimmerli; Parham Sendi
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

6.  Pathogenesis of foreign body infection. Evidence for a local granulocyte defect.

Authors:  W Zimmerli; P D Lew; F A Waldvogel
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

7.  Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants.

Authors:  M Drancourt; A Stein; J N Argenson; A Zannier; G Curvale; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

8.  Effect of treatment with methicillin and gentamicin in a new experimental mouse model of foreign body infection.

Authors:  F Espersen; N Frimodt-Møller; L Corneliussen; U Riber; V T Rosdahl; P Skinhøj
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

9.  Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space.

Authors:  T Mindermann; W Zimmerli; O Gratzl
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

10.  Low prevalence of tissue detection of cefepime and daptomycin used as empirical treatment during revision for periprosthetic joint infections: results of a prospective multicenter study.

Authors:  O Robineau; E Talagrand-Reboulh; B Brunschweiler; F Jehl; E Beltrand; F Rousseau; N Blondiaux; A Grillon; C Joseph; P Lambotte; P Boyer; Eric Senneville
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-05-20       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.